Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. (Q53093760)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

Adaptive radiation therapy

10 March 2020

main subject

0 references

phase II clinical trial

0 references

cisplatin

1 reference

inferred from title

cervix uterine cancer

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Isabele A Small

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Angelica Nogueira-Rodrigues

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Giulliana Moralez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Rachele Grazziotin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Claudio C Carmo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Flavia V G Alves

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Felipe Erlich

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Celia Viegas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sergio A Triginelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Carlos G Ferreira

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

10 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1187-1193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Human papillomaviruses as therapeutic targets in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

The epidermal growth factor receptor mediates radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Human papillomavirus in cervical and head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

Are we making progress in curing advanced cervical cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28471

7 January 2021

Identifiers

DOI

10.1002/CNCR.28471

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615735%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference